Determination of the Prevalence of Postcovid Syndrome and Assessment of the Effectiveness of the Drug Cortexin in the Treatment of Neurological Disorders in Patients with Postcovid Syndrome. Results of the CORTEX Multicenter Clinical and Epidemiological Observational Program.

Putilina, M V; Mutovina, Z Yu; Kurushina, O V; Khalilova, D M; Saverskaya, E N; Stepanova, S B; Khoreva, M A; Starikov, A S

Putilina, M V; Mutovina, Z Yu; Kurushina, O V; Khalilova, D M; Saverskaya, E N; Stepanova, S B; Khoreva, M A; Starikov, A S.

Afiliação

Putilina MV; Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
Mutovina ZY; City Clinical Hospital No. 52, Moscow Health Department, Moscow, Russia.
Kurushina OV; Volgograd State Medical University, Russian Ministry of Health, Volgograd, Russia.
Khalilova DM; Azerbaijan State Medical University, Baku, Azerbaijan.
Saverskaya EN; Moscow State University of Food Production, Moscow, Russia.
Stepanova SB; South Ural State Medical University, Russian Ministry of Health, Chelyabinsk, Russia.
Khoreva MA; Altai State Medical University, Russian Ministry of Health, Barnaul, Russia.
Starikov AS; Pitirim Sorokin Syktyvkar State University, Syktyvkar, Russia.

Neurosci Behav Physiol ; 52(6): 836-841, 2022.

Article em En | MEDLINE | ID: mdl-36311877

Palavras-chave

COVID-19; Cortexin; SARS-CoV-2; cognitive impairment; fatigue; olfactory impairment; postcovid syndrome; prevalence

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Evaluation_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google